{"pmid":32422441,"title":"Disinfection tunnels: potentially counterproductive in the context of a prolonged pandemic of COVID-19.","text":["Disinfection tunnels: potentially counterproductive in the context of a prolonged pandemic of COVID-19.","Public Health","Biswal, M","Kanaujia, R","Angrup, A","Ray, P","Mohan Singh, S","32422441"],"journal":"Public Health","authors":["Biswal, M","Kanaujia, R","Angrup, A","Ray, P","Mohan Singh, S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422441","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.puhe.2020.04.045","topics":["Prevention"],"weight":1,"_version_":1667254896671326208,"score":9.490897,"similar":[{"pmid":32291382,"title":"Coronavirus Vaccines: Light at the End of the Tunnel.","text":["Coronavirus Vaccines: Light at the End of the Tunnel.","The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here.","Indian Pediatr","Ella, Krishna M","Mohan, V Krishna","32291382"],"abstract":["The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here."],"journal":"Indian Pediatr","authors":["Ella, Krishna M","Mohan, V Krishna"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291382","source":"PubMed","week":"202016|Apr 13 - Apr 19","topics":["Treatment"],"weight":1,"_version_":1666138494445027330,"score":52.349377},{"pmid":32337139,"pmcid":"PMC7182165","title":"Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?","text":["Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?","Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First reported at the end of December 2019 as a cause for clusters of pneumonia cases in Wuhan city in China, the rapid spread of this condition was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). Apart from the mortality and morbidity associated with COVID-19, the massive social and financial havoc inflicted by this pandemic has left the entire world pondering if medical science can innovate and curtail the ongoing damage due to SARS-CoV-2. Recent findings of an open-label study that investigated the use of hydroxychloroquine and azithromycin in COVID-19 patients in Marseille, France, has garnered some optimism in scientific quarters and the general public alike in terms of finding a treatment regimen to control the rampant rise of COVID-19. We will discuss the potential off-label therapy and studies as it pertains to COVID-19.","Cureus","Sharma, Munish","Surani, Salim","32337139"],"abstract":["Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First reported at the end of December 2019 as a cause for clusters of pneumonia cases in Wuhan city in China, the rapid spread of this condition was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). Apart from the mortality and morbidity associated with COVID-19, the massive social and financial havoc inflicted by this pandemic has left the entire world pondering if medical science can innovate and curtail the ongoing damage due to SARS-CoV-2. Recent findings of an open-label study that investigated the use of hydroxychloroquine and azithromycin in COVID-19 patients in Marseille, France, has garnered some optimism in scientific quarters and the general public alike in terms of finding a treatment regimen to control the rampant rise of COVID-19. We will discuss the potential off-label therapy and studies as it pertains to COVID-19."],"journal":"Cureus","authors":["Sharma, Munish","Surani, Salim"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337139","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7759/cureus.7415","keywords":["azithromycin","coronavirus disease","hydroxychloroquine","sars-cov-2 (severe acute respiratory syndrome coronavirus -2)"],"locations":["Wuhan","China","Marseille","France"],"countries":["China","France"],"countries_codes":["CHN|China","FRA|France"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138494147231745,"score":44.897945}]}